secwatch.observer — SEC 8-K summary
======================================

Issuer:     Biomea Fusion, Inc. (BMEA)
CIK:        0001840439
Form:       8-K
Filed at:   2025-11-04T23:59:59+00:00
Accession:  0001193125-25-264631
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Biomea Q3 net loss $16.4M (down 50% YoY); cash $47M; advances icovamenib and BMF-650
--------------------------------------------------------------------------------

- Net loss $16.4M for Q3 2025 vs $32.8M in Q3 2024; R&D expenses down ~47% YoY.
- Cash, cash equivalents $47M as of Sep 30, 2025; raised ~$68M in two public offerings extending runway into Q1 2027.
- Icovamenib Phase II COVALENT-111: 1.5% mean HbA1c reduction at Week 52 in severe insulin-deficient T2D patients (p=0.01).
- BMF-650 (oral GLP-1 RA) dosed first patient in Phase I; 28-day weight reduction data expected H1 2026.
- Workforce reduced to ~40 employees as part of operational streamlining.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1840439/000119312525264631/0001193125-25-264631-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1840439/000119312525264631/bmea-20251104.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-264631

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer